Larimar Therapeutics Validates Skin Biomarker in FA
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
